# ACTIV-5 / Big Effect Trial (BET-A) for the Treatment of COVID-19

> **NCT04583956** · PHASE2 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 214 (actual)

## Conditions studied

- COVID-19

## Interventions

- **OTHER:** Placebo
- **DRUG:** Remdesivir
- **BIOLOGICAL:** Risankizumab

## Key facts

- **NCT ID:** NCT04583956
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-23
- **Primary completion:** 2021-09-13
- **Final completion:** 2021-09-13
- **Target enrollment:** 214 (ACTUAL)
- **Last updated:** 2023-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04583956

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04583956, "ACTIV-5 / Big Effect Trial (BET-A) for the Treatment of COVID-19". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04583956. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*